US biotech Dyne Therapeutics has moved closer to a possible first approval after the US Food and Drug Administration accepted ...

US biotech Regenxbio on Friday announced the pricing of an underwritten public offering of 10,003,889 shares of its common ...

A commercial-stage Chinese biopharmaceutical company pursuing BTK and TYK2 inhibition across oncology and autoimmune disease, ...

ExxPharma is a privately-held, New Jersey-based drug delivery and product development company. The company provides development and manufacturing services to discovery companies, and partners with ...

US pharma major Bristol Myers Squibb (NYSE: BMY) is expanding its partnership with NVIDIA (NASDAQ: NVDA), with plans to deploy an NVIDIA DGX SuperPOD built on DGX Vera Rubin NVL72 systems to support ...

USA-based biotech Latigo Biotherapeutics has thrown open its books to public investors, using a Friday filing with the Securities and Exchange Commission to reveal mid-stage results for its lead ...

Medicines regulators in major international markets have issued a mix of approvals, safety communications, recalls, ...

Last week saw AstraZeneca sign an accord with China’s Dizal Pharmaceutical for rights to the latter’s lung cancer drug ...

39-43 Putney High Street, Putney London, SW15 1SP United Kingdom ...

The US Food and Drug Administration (FDA) has accepted its supplemental New Drug Application (sNDA) for Zoryve (roflumilast) cream 0.05% to expand the indication for the topical treatment of mild to ...

Japan’s largest drugmaker Takeda (announced new Phase III data for zasocitinib, its investigational, next-generation, highly ...

US healthcare major Johnson & Johnson (NYSE: JNJ) reported second-quarter 2026 sales of $25.31 billion, up 6.6% on the year, ...